UCB (OTCMKTS:UCBJY) Shares Gap Down – Here’s What Happened

UCB SA (OTCMKTS:UCBJY) gapped down prior to trading on Monday . The stock had previously closed at $142.74, but opened at $134.70. UCB shares last traded at $134.58, with a volume of 784 shares trading hands.

Analyst Upgrades and Downgrades

A number of analysts recently commented on UCBJY shares. Barclays cut UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. Zacks Research raised UCB from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Jefferies Financial Group raised shares of UCB to a “moderate sell” rating in a research report on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy”.

UCB Trading Down 1.0%

The company has a current ratio of 1.38, a quick ratio of 1.04 and a debt-to-equity ratio of 0.20. The company’s fifty day moving average is $144.02 and its two-hundred day moving average is $148.05.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.